Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_1
3
75%
Ph phase_2
1
25%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

terminated250%
completed125%
active_not_recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
completedphase_1

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

NCT03985189
active_not_recruitingphase_2

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

NCT04533581
terminatedphase_1

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT04517435
terminatedphase_1

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

NCT02914938

Clinical Trials (4)

Showing 4 of 4 trials
NCT03985189Phase 1

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Completed
NCT04533581Phase 2

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

Active Not Recruiting
NCT04517435Phase 1

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated
NCT02914938Phase 1

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4